多巴胺受体激动剂治疗泌乳素瘤的机制及研究进展

[1] 垂体生长激素腺瘤的研究及治疗进展 [J]. 神经疾病与精神卫生, 2008, (02) : 158 - 160

[2] Somatostatin receptor sst2 gene transfer in human prolactinomas in vitro : Impact on sensitivity to dopamine, somatostatin and dopastatin, in the control of prolactin secretion[J] . Thomas Cuny,Amira Mohamed,Thomas Graillon,Catherine Roche,Céline Defilles,Anne-Laure Germanetti,Bettina Couderc,Dominique Figarella-Branger,Alain Enjalbert,Anne Barlier,Alexandru Saveanu.Molecular and Cellular Endocrinology . 2012 (1)

[3] Acquired resistance to cabergoline: progression from initially responsive micro to macroprolactinoma[J] . Pituitary . 2010 (4)

[4] Future treatment strategies of aggressive pituitary tumors [J]. PITUITARY, 2009, 12 (03) : 261 - 264

[5] Medical therapy of pituitary adenomas: Effects on tumor shrinkage[J] . Annamaria Colao,Rosario Pivonello,Carolina Somma,Silvia Savastano,Ludovica F. S. Grasso,Gaetano Lombardi.Reviews in Endocrine and Metabolic Disorders . 2009 (2)

[6] Invasive Giant Prolactinoma with Loss of Therapeutic Response to Cabergoline: Expression of Angiogenic Markers[J] . Endocrine Pathology . 2009 (1)

[7] Genes Differentially Expressed in Prolactinomas Responsive and Resistant to Dopamine Agonists [J]. NEUROENDOCRINOLOGY, 2009, 89 (02) : 163 - 170

[8] Pituitary tumor type affects the chance of biochemical remission after radiosurgery of hormone-secreting pituitary adenomas [J]. NEUROSURGERY, 2008, 62 (06) : 1271 - 1276

[9] Transsphenoidal adenomectomy for microprolactinomas: 10 to 20 years of follow-up[J] . Fadi Massoud,Omar Serri,Jules Hardy,Maurice Somma,Hugues Beauregard.Surgical Neurology . 1996 (4)

[10] Temozolomide-induced inhibition of pituitary adenoma cell s .2 SheehanJ,RaineyJ,NguyenJ,et al. J Neurosurg . 2011

[1] 垂体生长激素腺瘤的研究及治疗进展 [J]. 神经疾病与精神卫生, 2008, (02) : 158 - 160

[2] Somatostatin receptor sst2 gene transfer in human prolactinomas in vitro : Impact on sensitivity to dopamine, somatostatin and dopastatin, in the control of prolactin secretion[J] . Thomas Cuny,Amira Mohamed,Thomas Graillon,Catherine Roche,Céline Defilles,Anne-Laure Germanetti,Bettina Couderc,Dominique Figarella-Branger,Alain Enjalbert,Anne Barlier,Alexandru Saveanu.Molecular and Cellular Endocrinology . 2012 (1)

[3] Acquired resistance to cabergoline: progression from initially responsive micro to macroprolactinoma[J] . Pituitary . 2010 (4)

[4] Future treatment strategies of aggressive pituitary tumors [J]. PITUITARY, 2009, 12 (03) : 261 - 264

[5] Medical therapy of pituitary adenomas: Effects on tumor shrinkage[J] . Annamaria Colao,Rosario Pivonello,Carolina Somma,Silvia Savastano,Ludovica F. S. Grasso,Gaetano Lombardi.Reviews in Endocrine and Metabolic Disorders . 2009 (2)

[6] Invasive Giant Prolactinoma with Loss of Therapeutic Response to Cabergoline: Expression of Angiogenic Markers[J] . Endocrine Pathology . 2009 (1)

[7] Genes Differentially Expressed in Prolactinomas Responsive and Resistant to Dopamine Agonists [J]. NEUROENDOCRINOLOGY, 2009, 89 (02) : 163 - 170

[8] Pituitary tumor type affects the chance of biochemical remission after radiosurgery of hormone-secreting pituitary adenomas [J]. NEUROSURGERY, 2008, 62 (06) : 1271 - 1276

[9] Transsphenoidal adenomectomy for microprolactinomas: 10 to 20 years of follow-up[J] . Fadi Massoud,Omar Serri,Jules Hardy,Maurice Somma,Hugues Beauregard.Surgical Neurology . 1996 (4)

[10] Temozolomide-induced inhibition of pituitary adenoma cell s .2 SheehanJ,RaineyJ,NguyenJ,et al. J Neurosurg . 2011